Monday, June 15, 2026 | 01:45 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 4 - Indian Pharma Companies

Major fire engulfs garment, pharma factories in Noida, no casualty reported

A fire ripped through a garment factory here and spread to an adjoining pharmaceutical factory, prompting a major relief operation that lasted for more than eight hours and utilised services of over two dozen water tenders, officials said on Saturday. Chief Fire Officer (CFO) Pradeep Kumar said no one was injured in the incident that took place in B-Block of Sector 67. The fire service unit's control room received an alert call about the fire at 12 noon, he said. "We immediately sent eight vehicles to the spot but found that it was a major fire, which had spread from the garment factory to the adjoining pharmaceutical factory. This pharma factory was shut for the past two years but the items which were stocked inside caught the fire and intensified the blaze," Kumar said. "We had to deploy 28 vehicles and by 8.30 pm we were able to completely extinguish the fire. Fortunately, there was no injury to any person and no loss of life in the incident," the CFO said. Kumar said additiona

Major fire engulfs garment, pharma factories in Noida, no casualty reported
Updated On : 15 Jun 2024 | 11:01 PM IST

Pharmaceutical companies prepare to comply with ethical marketing code

Companies must commit that they comply with a code against unethical marketing of drugs

Pharmaceutical companies prepare to comply with ethical marketing code
Updated On : 30 May 2024 | 8:55 PM IST

Cipla rallies 4% on US FDA approval to market Lanreotide injection

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

Cipla rallies 4% on US FDA approval to market Lanreotide injection
Updated On : 22 May 2024 | 2:25 PM IST

Pharma major Glenmark gets USFDA nod for generic ophthalmic solution

Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions. The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement. The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2 per cent/0.5 per cent has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2 per cent/0.5 per cent of AbbVie, Inc, it added. The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added. Combigan ophthalmic solution, 0.2 per cent/0.5 per cent achieved annual sales of approximately USD 290 million, the company said citing IQVIATM sales data

Pharma major Glenmark gets USFDA nod for generic ophthalmic solution
Updated On : 17 May 2024 | 10:54 AM IST

Mankind Pharma open to acquisitions; board okays Rs 7,500 cr fundraise

The drug maker was reportedly interested in buying private equity (PE) firm Advent International's stake in Mumbai-based biopharma firm Bharat Serums and Vaccines (BSV)

Mankind Pharma open to acquisitions; board okays Rs 7,500 cr fundraise
Updated On : 16 May 2024 | 10:37 PM IST

Zydus Lifesciences gets China nod for drug to treat CKD-linked anaemia

It is estimated that more than 120 million people are living with chronic kidney disease in China

Zydus Lifesciences gets China nod for drug to treat CKD-linked anaemia
Updated On : 23 Apr 2024 | 5:08 PM IST

PE firm ChrysCapital invests $70 million in formulations company La Renon

Peak XV Partners (formerly Sequoia India) has been invested in La Renon since 2015, with A91 Emerging Fund joining in 2021

PE firm ChrysCapital invests $70 million in formulations company La Renon
Updated On : 16 Apr 2024 | 10:04 PM IST

MNCs partner Indian firms to boost market reach in pharmaceutical sector

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

MNCs partner Indian firms to boost market reach in pharmaceutical sector
Updated On : 29 Mar 2024 | 11:45 PM IST

Indian pharma companies bank on 'mother brands' to boost revenue growth

An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales

Indian pharma companies bank on 'mother brands' to boost revenue growth
Updated On : 27 Mar 2024 | 11:00 PM IST

Pharma firms bank on 'mother brands' to bolster new products: Report

A search conducted by Pharmarack showed that brands of any company, labelled under their mother brands, were observed to enjoy greater market share among their peers

Pharma firms bank on 'mother brands' to bolster new products: Report
Updated On : 27 Mar 2024 | 10:25 AM IST

Dr Reddy's, Pharmazz ink licence pact to commercialise resuscitative agent

With this agreement, India will become the first global territory where Centhaquin (Lyfaquin) is being launched immediately, according to the company

Dr Reddy's, Pharmazz ink licence pact to commercialise resuscitative agent
Updated On : 22 Mar 2024 | 8:24 PM IST

Sanofi India, Emcure Pharma announce exclusive distribution partnership

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business

Sanofi India, Emcure Pharma announce exclusive distribution partnership
Updated On : 13 Mar 2024 | 6:44 PM IST

Indian pharma cos make versions of Wegovy to get in on weight-loss windfall

Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026

Indian pharma cos make versions of Wegovy to get in on weight-loss windfall
Updated On : 22 Feb 2024 | 12:32 PM IST

Earnings downgrade a bitter pill for pharma major Divi's Labs stock

Gross margins improved by 313 basis points on a sequential basis to 60.7 per cent given lower raw material costs and improved product mix

Earnings downgrade a bitter pill for pharma major Divi's Labs stock
Updated On : 15 Feb 2024 | 10:09 PM IST

Aurobindo Pharma Q3 results: Profit up 91.43%, revenue rises 14.7%

The company's revenue from formulations increased by 17.2 per cent Y-o-Y to Rs 6,291 crore. Sequentially, it was up by 5.4 per cent from Rs 5,968 crore in Q2 FY24

Aurobindo Pharma Q3 results: Profit up 91.43%, revenue rises 14.7%
Updated On : 12 Feb 2024 | 6:39 PM IST

Launch delays key risk to outlook for pharma company Cipla stock

The company reported a 13.7 per cent increase in sales to Rs 6,603 crore led by 11.5 per cent growth in the India business

Launch delays key risk to outlook for pharma company Cipla stock
Updated On : 29 Jan 2024 | 10:11 PM IST

Slow improvement in sales could weigh on pharma firm Laurus' performance

Company reported lower-than-expected revenue after missing target in key segment

Slow improvement in sales could weigh on pharma firm Laurus' performance
Updated On : 26 Jan 2024 | 10:12 PM IST

Indian firms corner more of growing pharma market as MNCs go niche

Indian drug firms are focussing on expanding their salesforce and distri­bution, while getting into trade generics to garner volumes

Indian firms corner more of growing pharma market as MNCs go niche
Updated On : 25 Jan 2024 | 12:38 AM IST

Half of health, pharma cos to integrate GenAI solutions under 1 yr: Report

The report said that 28 per cent of healthcare and pharma companies had already implemented their first GenAI solutions

Half of health, pharma cos to integrate GenAI solutions under 1 yr: Report
Updated On : 24 Jan 2024 | 9:44 PM IST

Q3 result preview: US, India to aid revenue growth for Pharma Inc

In the healthcare segment, hospitals are expected to post revenue growth of 13 percent during the coverage, while the net profit growth would be around 37 percent, ICICI Securities said in a note

Q3 result preview: US, India to aid revenue growth for Pharma Inc
Updated On : 22 Jan 2024 | 10:50 PM IST